Interactive Features

Quiz

Nirogacestat in Young Adult Patients With Desmoid Tumors

10/08/2026

Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.

Test your knowledge of...

10/08/2026

Oncology

FDA Alerts

FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors

07/09/2026

Emily Estrada

The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...

The FDA accepted the new drug...

07/09/2026

Oncology

Quiz

Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors

06/19/2026

What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?

What was the effect of pegylated...

06/19/2026

Oncology

Recent News

FDA Approval

FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer

10/14/2026

Emily Estrada

The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...

The FDA expanded the indication...

10/14/2026

Oncology

News

Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors

10/09/2026

Emily Estrada

Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...

Results from a phase 3 trial...

10/09/2026

Oncology

News

Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma

10/08/2026

Stephanie Holland

Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...

Topline results from the phase 3...

10/08/2026

Oncology

News

Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes

10/08/2026

Emily Estrada

Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...

Results from a small study...

10/08/2026

Oncology

News

Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes

10/08/2026

Emily Estrada

A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...

A retrospective analysis of...

10/08/2026

Oncology

News

Epcoritamab Plus R-CHOP Improves Progression-Free Survival Over R-CHOP Alone in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma

10/08/2026

Emily Estrada

Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...

Topline results from the phase 3...

10/08/2026

Oncology

News

SurVaxM Shows Survival Signal in Newly Diagnosed Glioblastoma, With Significant Benefit in Younger Patients

10/07/2026

Emily Estrada

Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...

Results from the phase 2b...

10/07/2026

Oncology

FDA Approval

FDA Approves Tucatinib Plus Trastuzumab and Pertuzumab for Maintenance Treatment of HER2-Positive Advanced Breast Cancer

10/07/2026

Stephanie Holland

Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...

Based on results from the...

10/07/2026

Oncology

FDA Approval

FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion

10/02/2026

Stephanie Holland

Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...

Based on results from BRUIN...

10/02/2026

Oncology

News

Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer

09/29/2026

Emily Estrada

Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...

Results from the phase 3...

09/29/2026

Oncology